ARTICLE | Clinical News
NKTR-102: Phase III ongoing
January 20, 2014 8:00 AM UTC
Nektar said an independent DMC recommended continuation of the open-label, international Phase III BEACON trial of NKTR-102 following a planned interim efficacy analysis which included 50% of patient ...